Adrenoleukodystrophy

Adrenoleukodystrophy
Adrenoleukodystrophy
Synonyms	ALD, X-linked adrenoleukodystrophy
Pronounce
Specialty	Neurology, Endocrinology
Symptoms	Seizures, hyperactivity, vision problems, hearing loss, adrenal insufficiency
Complications	N/A
Onset	Childhood, adulthood
Duration	Progressive
Types	Childhood cerebral, adrenomyeloneuropathy, Addison-only
Causes	Mutations in the ABCD1 gene
Risks	Family history
Diagnosis	Genetic testing, MRI, blood test for very long chain fatty acids
Differential diagnosis	Multiple sclerosis, metachromatic leukodystrophy, Zellweger syndrome
Prevention	N/A
Treatment	Lorenzo's oil, hematopoietic stem cell transplantation, adrenal hormone replacement
Medication
Prognosis	Variable, depends on type and age of onset
Frequency	1 in 20,000 to 50,000 people
Deaths

Genetic disorder affecting the nervous system and adrenal glands

Adrenoleukodystrophy (ALD) is a rare, genetic disorder characterized by the breakdown or loss of myelin, the fatty covering surrounding nerve cells in the brain, and progressive dysfunction of the adrenal glands. It is an X-linked disorder, meaning it predominantly affects males, although female carriers can also exhibit symptoms.

Genetics

File:ABCD1-gene.svg

Diagram of the ABCD1 gene location on the X chromosome

ALD is caused by mutations in the ABCD1 gene located on the X chromosome. This gene encodes a protein that is part of the ATP-binding cassette (ABC) transporter family, which is involved in the transport of very long-chain fatty acids (VLCFAs) into peroxisomes for degradation. Mutations in the ABCD1 gene lead to the accumulation of VLCFAs in tissues, particularly affecting the nervous system and adrenal cortex.

Pathophysiology

The accumulation of VLCFAs in the central nervous system leads to the destruction of myelin, the protective sheath surrounding nerve fibers. This demyelination process disrupts the normal transmission of nerve impulses, resulting in neurological symptoms. In the adrenal glands, VLCFA accumulation impairs the production of adrenal hormones, leading to adrenal insufficiency.

Clinical Presentation

The clinical presentation of ALD can vary widely, but it is generally categorized into several phenotypes:

• Childhood cerebral ALD: This is the most severe form, typically presenting between ages 4 and 10. It is characterized by rapid neurological decline, including behavioral changes, vision and hearing loss, motor dysfunction, and eventually, severe disability or death.

• Adrenomyeloneuropathy (AMN): This adult-onset form presents with progressive stiffness and weakness in the legs, bladder dysfunction, and sexual dysfunction. It is less severe than the childhood form but can lead to significant disability.

• Addison-only phenotype: Some individuals present primarily with adrenal insufficiency without significant neurological symptoms.

Diagnosis

Diagnosis of ALD is based on clinical presentation, family history, and biochemical testing for elevated VLCFA levels in the blood. Genetic testing can confirm mutations in the ABCD1 gene. MRI imaging is used to assess the extent of demyelination in the brain.

Treatment

There is no cure for ALD, but treatment focuses on managing symptoms and slowing disease progression. Options include:

• Lorenzo's oil: A mixture of oleic and erucic acids that can reduce VLCFA levels in the blood.
• Hematopoietic stem cell transplantation (HSCT): This can be effective in early stages of cerebral ALD.
• Adrenal hormone replacement therapy: For those with adrenal insufficiency.

Prognosis

The prognosis of ALD varies depending on the phenotype and age of onset. Childhood cerebral ALD has a poor prognosis without treatment, while AMN progresses more slowly. Early diagnosis and intervention can improve outcomes.

Related pages

• X-linked recessive inheritance
• Peroxisomal disorder
• Demyelinating disease